Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics (NKTR) Chief Legal Officer Mark A. Wilson reported equity award activity. On 11/21/2025, he acquired 1,903 shares of common stock through vesting of previously granted restricted stock units under the company’s 2017 Performance Incentive Plan, following the Compensation Committee’s determination on November 20, 2025 that the performance conditions were met. After this, he beneficially owned 22,215 shares, including shares held in the employee stock purchase plan.
On 11/25/2025, he sold 630 shares to cover tax withholding obligations related to the RSU vesting, leaving 21,585 shares held directly. He also received a grant of 3,400 stock options on 11/21/2025 with an exercise price of $281.25 per share, vesting after the performance-based condition was determined to be satisfied and subject to time-based vesting through December 17, 2028.
Nektar Therapeutics (NKTR) reported insider activity by President & CEO and director Mark A. Wilson. On 11/21/2025, he acquired 7,110 shares of common stock at $0 following the vesting of previously granted restricted stock units. On 11/25/2025, he sold 2,207 shares at a weighted average price of $54.28 to cover tax withholding obligations related to this vesting, which the filing notes was not a discretionary trade. After these transactions, he directly held 54,245 shares of common stock and indirectly held 28 shares through his spouse. In addition, 12,170 stock options with an exercise price of $281.25, expiring on 12/17/2028, vested on 11/21/2025.
Nektar Therapeutics announced that Mark A. Wilson will step down as Chief Legal Officer, effective December 31, 2025. The company states that his departure is not due to any disagreement regarding Nektar’s operations, policies, or practices, which indicates this is presented as an orderly transition rather than a dispute-driven change.
Elizabeth Zhang, currently Vice President, Legal and Corporate Counsel, will assume Mr. Wilson’s responsibilities. She joined Nektar in 2021 and previously worked at major law firms Cravath, Swaine & Moore LLP and Gibson, Dunn & Crutcher LLP. Ms. Zhang holds degrees from Harvard College, the University of Oxford, and Harvard Law School, suggesting continuity in legal leadership with a strong academic and professional background.
Nektar Therapeutics filed a Form S-8 to register 250,000 shares of common stock (par value $0.0001) reserved for issuance under its 2025 Inducement Plan.
The Board adopted the plan on November 6, 2025, without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The plan will be administered by the Organization and Compensation Committee.
Eligibility is limited to individuals who meet Nasdaq’s inducement grant standards. Permitted awards include nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, stock bonuses, and other stock-based awards. This registration facilitates equity grants used to attract and hire qualified talent under the inducement exception.
Nektar Therapeutics launched an at-the-market offering to sell up to $110,000,000 of common stock under an Equity Distribution Agreement with Piper Sandler & Co. and BTIG, LLC. Sales may occur from time to time as “at the market offerings” under Rule 415, and the agents will use commercially reasonable efforts. The program is part of Nektar’s existing $300,000,000 shelf registration. The sales agents are deemed underwriters and will receive a 3.0% commission on gross sales.
Nektar plans to use net proceeds for general corporate purposes, including research and clinical development of rezpegaldesleukin, NKTR‑0165, and NKTR‑255, plus working capital and potential investments. Nektar’s common stock trades on Nasdaq as NKTR; the last reported sale price was $57.97 per share on November 10, 2025. Shares outstanding were 19,652,513 as of September 30, 2025.
Nektar Therapeutics furnished new clinical results from its ongoing Phase 2b REZOLVE-AD trial in atopic dermatitis. The study enrolled 393 patients; a pre-planned analysis of 99 participants with a history of asthma and ACQ-5 data showed all three rezpegaldesleukin doses reduced mean ACQ-5 scores at week 16, with the 24 μg/kg q2w and 24 μg/kg q4w arms reaching p<0.05 versus placebo. The placebo arm showed overall worsening.
Among patients with baseline ACQ-5 ≥0.5 (n=53), at least half achieved a clinically significant improvement across all active arms, compared to 13% for placebo. In those with uncontrolled asthma at baseline (ACQ-5 ≥1.5; n=25), all active doses improved mean ACQ-5 at week 16 with statistical significance, with placebo-adjusted reductions ranging 1.0–1.4. In a crossover cohort of 42 initial placebo patients treated with 24 μg/kg q2w, observed responses at crossover week 24 were: EASI-75 60% (n=30), vIGA-AD 0/1 33% (n=30), EASI-90 37% (n=30), and Itch NRS 50% for baseline ≥4 (n=28). Safety was generally consistent with the previously reported profile.
Nektar Therapeutics filed its Q3 2025 10‑Q, reporting continued operating losses alongside a strengthened cash position. Total revenue was $11.8 million, primarily from non‑cash royalty revenue related to prior royalty sales, down from $24.1 million a year ago. The company reported a net loss of $35.5 million for the quarter and $128.0 million year‑to‑date.
Cash, cash equivalents and marketable securities totaled $270.2 million as of September 30, 2025. During the quarter, Nektar completed an underwritten public offering of 4,893,618 shares at $23.50 per share for approximately $107.2 million in net proceeds, issued 600,198 shares under its at‑the‑market program for $34.3 million in net proceeds, and saw exercise of a 1,666,667‑share pre‑funded warrant. A one‑for‑fifteen reverse stock split became effective on June 8, 2025.
Following the December 2024 sale of its Huntsville manufacturing facility, Nektar no longer records product sales and recognized a $0 product sales line this quarter. The company continues Phase 2b programs for rezpegaldesleukin and recorded a small loss from its equity method investment in Gannet BioChem.
Nektar Therapeutics filed an 8-K stating it has furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company attached the press release as Exhibit 99.1 titled “Nektar Therapeutics Reports Third Quarter 2025 Financial Results.”
The information is furnished under Item 2.02 and is expressly stated as not deemed “filed” under Section 18 of the Exchange Act and not incorporated by reference into other SEC filings. Nektar’s common stock trades on the Nasdaq Capital Market under the symbol NKTR.
Nektar Therapeutics director Roy A. Whitfield was granted 8,000 stock options on 09/30/2025. The option award has an exercise price of $56.90 and an expiration date of 09/29/2033. The filing shows the options are directly beneficially owned by the reporting person and will vest in substantially equal monthly installments over the one-year period beginning on September 30, 2025.
NEKTAR THERAPEUTICS (NKTR) Form 4 summary: Director Greer R. Scott received a non-derivative award in the form of a stock option grant on 09/30/2025 for 8,000 options with a stated conversion/exercise price of $56.90. The reported option is exercisable beginning 09/29/2033 and the filing shows 8,000 shares benefically owned following the transaction, held directly. The filing notes the option vests in substantially equal monthly installments over the one-year period beginning on 09/30/2025. The form was signed by an attorney-in-fact on 10/01/2025. The document discloses a standard director compensation award rather than a sale or disposition.